Lincoln Capital Corp’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Lincoln Capital Corp’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-17,000	Closed	-$16K	–	59
2018 Q3	$16K	Buy	+17,000	New	+$28.4K	0.01%	48

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

MFGP

Marshall Financial Group (Pennsylvania) Doylestown, Pennsylvania $364M AUM 12.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lincoln Capital Corp's PTX Position: Q4 2018 in Review

Lincoln Capital Corp sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q4 2018, closing a stake of 17,000 shares — an estimated $16K sold.

Lincoln Capital Corp first reported a position in PTX in Q3 2018 and held it in 1 quarter. The position peaked at $16K in Q3 2018. 32 funds tracked by Wall St. Rank hold PTX as of Q4 2018.

Lincoln Capital Corp reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
Lincoln Capital Corp sold 17,000 Pernix Therapeutics Holdings, Inc. shares in Q4 2018, an estimated $16K.
Lincoln Capital Corp first reported a position in Pernix Therapeutics Holdings, Inc. in Q3 2018 and held it in 1 quarter.
Lincoln Capital Corp's Pernix Therapeutics Holdings, Inc. position peaked at $16K in Q3 2018.
32 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2018.

Based on Lincoln Capital Corp's 13F filing for Q4 2018, filed 22 Jan 2019.